PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
0.93%
Positive ROE while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch would see if the firm holds a competitive advantage in a struggling sector.
0.74%
Positive ROA while Drug Manufacturers - Specialty & Generic median is negative. Philip Fisher would see if the firm has a stronger model than peers.
0.24%
ROCE of 0.24% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if moderate profitability can widen vs. peers.
26.23%
Gross margin 50-75% of Drug Manufacturers - Specialty & Generic median of 48.08%. Guy Spier would question if commodity-like dynamics exist.
8.57%
Margin of 8.57% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if moderate profitability can be leveraged further.
28.44%
Net margin of 28.44% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss would examine if modest profitability can expand.